Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: An effect of decelerated aging?

American Journal of Hypertension

Volumn 21, Issue 2, 2008, Pages 177-182

  Baumann, Marcus ^a,b   Bartholome, Roger ^a   Peutz Kootstra, Carine J ^a   Smits, Jos F M ^a   Struijker Boudier, Harry A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CYCLINE; HYDRALAZINE; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; ATROPHY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; INTERSTITIAL NEPHRITIS; KIDNEY CELL; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TELOMERE;

AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELL CYCLE; CELL DIVISION; HYPERPLASIA; HYPERTENSION, RENAL; KIDNEY TUBULES; LOSARTAN; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 38949084209     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.30     Document Type: Article

References (30)

1. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
2. Aviv A, Zahorodny W. Telomeres: the time factor in essential hypertension. Curr Hypertens Rep 2001; 3:33-35.
3. Hamet P, Thorin-Trescases N, Moreau P, Dumas P, Tea BS, deBlois D, Kren V, Pravenec M, Kunes J, Sun Y, Tremblay J. Workshop: excess growth and apoptosis: is hypertension a case of accelerated aging of cardiovascular cells? Hypertension 2001; 37:760-766.
4. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, Dolbier C, Mendes WB, Blackburn EH. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology 2005; 31:277-287.
5. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000; 36:195-200.
6. Thorin-Trescases N, deBlois D, Hamet P. Evidence of an altered in vivo vascular cell turnover in spontaneously hypertensive rats and its modulation by long-term antihypertensive treatment. J Cardiovasc Pharmacol 2001; 38:764-774.
7. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J. Apoptosis in target organs of hypertension. Hypertension 1995; 26:642-648.
8. Dickhout JG, Lee RM. Apoptosis in the muscular arteries from young spontaneously hypertensive rats. J Hypertens 1999; 17:1413-1419.
9. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360:361-364.
10. Tanner FC, Greutert H, Barandier C, Frischknecht K, Luscher TF. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension 2003; 42:184-188.
11. Diep QN, El Mabrouk M, Touyz RM, Schiffrin EL. Expression of cell cycle proteins in blood vessels of angiotensin II-infused rats: role of AT(1) receptors. Hypertension 2001; 37:604-608.
12. Demirci B, McKeown PP, Bayraktutan U. Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 2005; 23:2219-2227.
13. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128:247-252.
14. Brannstrom K, Morsing P, Arendshorst WJ. Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors. Am J Physiol 1996; 270:F749-F755.
15. Cheng HF, Wang JL, Vinson GP, Harris RC. Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule. Am J Physiol 1998; 274:F10-F17.
16. Henrich WL, Levi M. Ontogeny of renal renin release in spontaneously hypertensive rat and Wistar-Kyoto rat. Am J Physiol 1991; 260:F530-F535.
17. Baumann M, Janssen BJ, Hermans JR, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 2007; 25:207-215.
18. Sanz-Rosa D, Oubina MP, Cediel E, De las Heras N, Aragoncillo P, Balfagon G, Cachofeiro V, Lahera V. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 2005; 7:1294-1301.
19. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47:467-474.
20. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30:e47.
21. Serrano AL, Andres V. Telomeres and cardiovascular disease: does size matter? Circ Res 2004; 94:575-584.
22. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28:803-812.
23. Hector Polizio A, Pena C. Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept 2005; 128:1-5.
24. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Temporary angiotensin ii blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711.
25. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93:2578-2583.
26. Nozato T, Ito H, Tamamori M, Adachi S, Abe S, Marumo F, Hiroe M. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Jpn Circ J 2000; 64:595-601.
27. Hadrava V, Tremblay J, Sekaly RP, Hamet P. Accelerated entry of aortic smooth muscle cells from spontaneously hypertensive rats into the S phase of the cell cycle. Biochem Cell Biol 1992; 70:599-604.
28. Aviv A, Aviv H. Reflections on telomeres, growth, aging, and essential hypertension. Hypertension 1997; 29:1067-1072.
29. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
30. Skov K, Eiskjaer H, Hansen HE, Madsen JK, Kvist S, Mulvany MJ. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007; 50:89-95.